Abacus Insights, which seeks to make health care data more interoperable in the US, raises $35M Series B led by Blue Venture Fund, bringing total raised to $53M
Katie Jennings / Forbes :
Context & Ripple Effects
Abacus Insights' $12.7M Series A in mid-2019 positioned it as a data integration platform for health insurers; the new $35M Series B from Blue Venture Fund roughly quadruples its total raised to $53M and extends that thesis into a market where capital is piling up fast. Just months before this round, Innovaccer pulled in a $70M Series C for a competing single-source patient data platform.
The round lands Abacus in an increasingly well-funded lane: Clarify Health's $150M Series D later reached a reported $1.4B valuation on analytics covering 300M+ Americans, while H1 Insights and Kyruus raised in the same 2020 window for adjacent health-data and analytics services. The Series B is effectively Abacus' ticket to stay competitive in that arms race.
First-order effects
- Abacus Insights gains $35M led by Blue Venture Fund to scale its payer-focused data integration platform, moving from Series A validation to a funded build-out against better-capitalized rivals.
Second-order effects
- Innovaccer, which raised $70M months earlier for a similar single-source-of-truth platform, faces a rival with fresh capital and a Blue Venture Fund backer whose health-system ties can open payer doors.
Third-order effects
- If the funding pattern across Abacus, Innovaccer, Clarify Health, and XCures holds, health care data interoperability consolidates into a few heavily capitalized platforms that payers and providers plug into, raising the capital bar for new entrants.
The trend: US health care data integration is becoming a capital-intensive platform market, with successive large rounds concentrating interoperability among a handful of funded players.